HUNTINGTON’S DISEASE – Leaf411

HUNTINGTON’S DISEASE: a progressive brain disorder caused by a defective gene

2024
Cannabidiol and neuro-degeneration: from molecular mechanisms to clinical benefits. https://www.sciencedirect.com/science/article/abs/pii/S1568163724002046
2023
A single-center, real-life study on the use of medical cannabis in patients with dystonia. https://www.frontiersin.org/articles/10.3389/fneur.2023.1218300/full
2019
Cannabinoids and the expanded endocannabinoid system in neurological disorders. (Italy/ Canada, abstract, 2019) https://www.nature.com/articles/s41582-019-0284-z
Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model. (Canada/ Saudi Arabia/ USA, abstract, 2019) https://www.semanticscholar.org/paper/Positive-allosteric-modulation-of-the-type-1-the-of-Laprairie-Bagher/81e262da611f8f17720aa46d63b5751154ad66bb
Chapter Eight - Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders. (Spain, abstract, 2019) https://www.sciencedirect.com/science/article/pii/S0074774219300327?via%3Dihub
Alterations in synaptic function and plasticity in Huntington disease. (Canada, full, 2019) https://onlinelibrary.wiley.com/doi/full/10.1111/jnc.14723
Huntington’s Disease and Medical Marijuana. (news – 2019)
https://www.solevowellness.com/marijuana-huntingtons-disease/
2018
Behavioral symptoms in premanifest Huntington disease correlate with reduced frontal CB1R levels. (Belgium, abstract, 2018) https://pubmed.ncbi.nlm.nih.gov/29934407/
Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington’s Disease. (Canada/ Saudi Arabia, abstract, 2018) https://link.springer.com/protocol/10.1007%2F978-1-4939-7825-0_25
Cannabinoids for Treatment of Dystonia in Huntington's Disease. (Germany/ Austria, abstract, 2018) https://pubmed.ncbi.nlm.nih.gov/29562549/
Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. (Spain, PDF, 2018) https://www.semanticscholar.org/paper/Cannabinoid-pharmacology%2Ftherapeutics-in-chronic-Aymerich-As%C3%B3/2e9946a36f70b0f5e320459b0f8f7a7125c72bdc
Insight into the emerging role of striatal neurotransmitters in the pathophysiology of Parkinson's disease and Huntington's disease: A review. (India, full, 2018) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343208/
Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease. (USA, full, 2018) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098121/
2017
Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? (Italy/ Spain/ Germany, abstract, 2017) https://pubmed.ncbi.nlm.nih.gov/28276775/
Analysis of Natural Product Regulation of Cannabinoid Receptors in the treatment of Human Disease. (USA/ Jamaica, abstract, 2017) https://www.sciencedirect.com/science/article/abs/pii/S0163725817301511
Neurological aspects of medical use of cannabidiol. (Italy, abstract, 2017) https://www.ingentaconnect.com/contentone/ben/cnsnddt/2017/00000016/00000005/art00006
Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model. (Canada/ USA, full, 2017) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777109/
Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity. (Spain/ USA/ Italy, full, 2017) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731255/
Endocannabinoid System in Neurodegenerative Disorders. (USA, full, 2017) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669051/
A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders. (Singapore, full, 2017) http://www.cpn.or.kr/journal/view.html?volume=15&number=4&spage=301
Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid. (Israel, full, 2017) https://www.mdpi.com/1422-0067/18/8/1669/htm
Neuroprotective effect of WIN55,212-2 against 3-nitropropionic acid-induced toxicity in the rat brain: involvement of CB1 and NMDA receptors. (Mexico, full, 2017) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340665/
Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease. (Spain, full, 2017) https://www.mdpi.com/1422-0067/18/4/684/htm
Molecular Imaging Markers to Track Huntington’s Disease Pathology (UK, full, 2017) https://www.frontiersin.org/articles/10.3389/fneur.2017.00011/full
Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target. (Italy, full, 2017) https://www.frontiersin.org/articles/10.3389/fnins.2017.00030/full
Weeding out the truth: can cannabis improve Huntington’s? (news – 2017) https://en.hdbuzz.net/234
THCA Shows Promise for Huntington’s Disease, Study Finds. (news – 2017)
https://www.leafly.com/news/science-tech/thca-shows-promise-for-huntingtons-disease-study-finds
2016
Marijuana May Boost Brain Performance (news–2016) http://www.worldhealth.net/news/marijuana-may-boost-brain-performance/
2015
What ailments does medical marijuana help? (news-2015) http://www.mnn.com/health/fitness-well-being/stories/what-ailments-does-medical-marijuana-help
2014
Report On Medical Cannabis Research, What the Science Says (article-2014) http://www.safeaccessnow.org/medical_cannabis_research_what_does_the_evidence_say
An Overview of Huntington’s Disease and Cannabis (news–2014) https://www.medicaljane.com/2014/11/18/huntingtons-disease-and-medical-marijuana/
2011
THC for Huntington’s Disease? CB1 receptors important for more than drug use (news–2011) https://www.psychologytoday.com/blog/all-about-addiction/201102/thc-huntingtons-disease-cb1-receptors-important-more-drug-use